Commit Biologics is creating a new drug category in immunotherapy by harnessing one of the immune system’s most ancient and powerful effector functions: complement. Our proprietary Bispecific Complement Engager (BiCE™) platform creates complement-powered immune engagers designed to selectively eliminate diseased cells. By recruiting C1q directly to malignant or pathological cells, BiCE™ antibodies activate complement precisely where it is needed, driving rapid and potent killing through a mechanism that does not rely on T cells. Building on three decades of complement research at Aarhus University, we spent years at Commit investigating how to design effective complement-powered immune engagers. That work produced the BiCE™ platform and, more recently, our first drug candidate, which is now heading to the clinic. We expect complement-powered immune engagers to become a new pillar of immunotherapy, alongside T cell engagers and cell therapies. Commit is backed by Bioqube Ventures, Novo Holdings, Korys and the BioInnovation Institute.
| Website | https://commitbio.com/ |
| Employees | 33 (19 on RocketReach) |
| Founded | 2021 |
| Phone | +45 30 49 70 99 |
| Industry | Biotechnology |
| Keywords | Cancer Therapies, Autoimmune Disease Treatment, Biopharmaceutical, Immunology, Oncology, Immunotherapy, Precision Medicine, Biotechnology, Drug Development, Therapeutic Antibodies, Novel Therapeutics, Clinical Stage, Preclinical Development, Pharmaceutical Research, Biologics, Cell Therapy, Protein Therapeutics |
| Competitors | Cohere Health, Amgen, Receptos, a wholly-owned subsidiary of Celgene, アステラス製薬(株), Genentech, Biogen, Illumina, Novartis, Gilead Sciences, Regeneron +47 more (view full list) |
Looking for a particular Commit Biologics employee's phone or email?
Thomas Andresen is the CEO of Commit Biologics.
19 people are employed at Commit Biologics.